36725-28-7: Levosimendan Inhouse Impurity
It is an impurity present in Levosimendan, Levosimendan increases myofilament calcium sensitivity by binding to cardiac troponin C in a calcium-dependent manner. by stabilizing the calcium-induced conformational change of troponin C by changing actin-myosin. cross-bridge kinetics apparently without increasing the cycling rate of the cross bridges increasing the effects of calcium on cardiac myofilaments during systole, also have a selective phosphodiesterase (PDE)-III inhibitory action. levosimendan acts preferentially as a Ca2+ sensitizer at lower concentrations whereas at higher concentrations its action as a PDE-III inhibitor becomes more prominent in experimental animals and humans.
Additional information on CAS 36725-28-7
VE006147
36725-28-7
C11H13N3O
203.24 g/mol
Levosimendan
6-(4-Aminophenyl)-4, 5-dihydro-5-methyl-3(2H)-pyridazinone
N/A
Nieminen, M. S., Fruhwald, S., Heunks, L. M. A., Suominen, P. K., Gordon, A. C., Kivikko, M., & Pollesello, P. (2013). Levosimendan: current data, clinical use and future development. Heart, Lung and Vessels, 5(4), 227–245. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868185/
In-stock
